This article is more than 5 years old. Information may no longer be current.

Takeda, Lilly to market diabetes drug jointly in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A drug to treat microvascular complications of diabetes, currently undergoing phase 2 trials in Japan, will be comarketed by Eli Lilly and Co. and Takeda Chemical Industries once regulatory approval is granted, according to a Reuters report. Among the targeted complications of the drug is diabetic retinopathy.

The drug, dubbed LY-333531, is also in late-stage clinical trials in the United States and Europe, according to Reuters.